Akkermansia muciniphila is an anaerobic species of gut microbiome that has been proposed as a new functional microbiota with probiotic properties. Recent research has shown the amazing abilities of probiotic bacteria, A. muciniphila, which resides in most people's intestines. These bacteria affect the body if it increases or decreases abdominal fat. The presence of A. muciniphila has opened new ways for the use of this plentiful intestinal symbiont in next-generation therapeutic products, as well as targeting microbiota dynamics. A. muciniphila is particularly effective in increasing mucosal thickness and enhancing bowel barrier function. As a result, host metabolic markers improve. The host functions that are disrupted in various diseases with a particular focus on metabolic disorders in animals and humans. A specific protein in the outer membrane of A. muciniphila called Amuc-110 could in the future be a strong candidate for drug production. As a result, we suggest that microbes and our microbiology or gut microbiome knowledge could be a new source for future treatments. The objectives of this review are to summarize the data available on the distribution of A. muciniphila gut in health and disease, to provide insights into the environment and its role in the creation of microbial networks at the mucosal interface, as well as to discuss recent research on its role in regulation.